What is a Clinical Pathway Handbook for Hyperbilirubinemia?
What was originally developed as a Quality-Based Procedure (QBP) for Hyperbilirubinemia has been revised and updated into a best evidence Clinical Pathway for Hyperbilirubinemia in Term and Late Pre-Term Infants (> 35 weeks).
The key objectives of the Clinical Pathway Handbook for Hyperbilirubinemia in Term and Late Pre-Term Infants (≥ 35 weeks) are to:
- Ensure all newborns receive bilirubin screening between 24-72 hours of life (if not clinically indicated and performed earlier)
- Ensure infants receive systematic bilirubin monitoring as per the treatment graph and risk nomograms recommended by evidence-based guideline
- Utilize health care resources responsibly through avoidance of unnecessary/excessive testing, timely discharge, appropriate outpatient follow-up and minimization of preventable readmission
- Reduce the incidence of severe hyperbilirubinemia and acute bilirubin encephalopathy
A revised and updated version of the QBP for Hyperbilirubinemia.
A brief update of the changes made to the Clinical Pathway Handbook for Hyperbilirubinemia in Term and Late Pre-Term Infants (> 35 weeks).
An abridged version of the Clinical Pathway Handbook focusing on the clinical pathway.
Previously offered February 21st, 2014 and March 4th, 2014.
This document was developed based on questions from the February 21st, 2014 and March 4th 2014 webinar sessions.